FindTrial
Sign In

A real-world study on the efficacy and safety of recombinant human growth hormone therapy in children with Idiopathic short stature

A real-world study on the efficacy and safety of recombinant human growth hormone therapy in children with idiopathic short stature

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078196
Enrollment
Unknown
Registered
2023-11-30
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic short stature

Interventions

GH group:NA

Sponsors

Fuzhou Children's Hospital of Fujian
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 9 Years

Inclusion criteria

Inclusion criteria: Meet the diagnosis of idiopathic short stature

Exclusion criteria

Exclusion criteria: Existence of severe organic lesions; Accompanied by severe congenital diseases or decreased liver and kidney function; There is a drug allergic reaction to growth hormone; Use drugs that affect the growth of the child in the near future.

Design outcomes

Primary

MeasureTime frame
IGF-1;Height standard deviation;—

Secondary

MeasureTime frame
Height growth rate;—

Countries

CHINA

Contacts

Public ContactRuimin Chen

Fuzhou Children's Hospital of Fujian

chenrm321@163.com+86 591 8711 6321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026